Trump signed an executive order on April 18 titled "Accelerating Medical Treatments for Serious Mental Illness." It directs the FDA to issue priority review vouchers for psychedelic drugs with breakthrough therapy designations — three vouchers immediately for psilocybin and MDMA, with decisions expected this summer. It opens a Right to Try pathway for investigational psychedelics including ibogaine, allocates $50 million through ARPA-H for state psychedelic programs, and orders the Attorney General to review drug scheduling after Phase 3 trials. RFK Jr., the HHS Secretary who took LSD at 15 and calls psychedelic therapy a "tremendous advantage," was at the signing. So was Joe Rogan.

1. The Science Is There. The Bureaucracy Wasn't. (Compass Pathways, MAPS, Veterans Groups)

67% of PTSD patients in remission after three MDMA sessions. The FDA said no anyway.

The clinical evidence for psychedelics has outrun the regulatory process. Phase 3 trials of MDMA-assisted therapy showed 67% of participants no longer met PTSD criteria after three sessions. Compass Pathways hit primary endpoints in two separate Phase 3 psilocybin trials for treatment-resistant depression — one in June 2025 and another in early 2026. Cybin's Phase 2 showed a 71% remission rate for major depressive disorder. The science isn't preliminary — it's Phase 3.

The FDA rejected MDMA anyway, and the reasons were debatable. The agency issued a complete response letter in August 2024 citing concerns about durability, cardiovascular risks, and "functional unblinding" — patients could tell they took MDMA because of the subjective effects. Critics of the rejection argued the FDA applied an unreasonably high bar to a breakthrough-designated therapy for a condition with limited treatment options.

Veterans drove the politics. Sen. Tim Sheehy, a Navy SEAL veteran, introduced a bill requiring the VA to evaluate psychedelic treatments. It received the first-ever unified endorsement from three leading veteran psychedelic organizations: Heroic Hearts Project, Veterans Exploring Treatment Solutions, and the Veteran Mental Health Leadership Coalition. Bipartisan co-sponsors include Sens. Gallego, Duckworth, and Boozman. The House unanimously backed psychedelic research amendments in FY2024 appropriations.

2. This Is Being Rushed, and People Will Get Hurt (FDA Scientists, Nora Volkow, Yale)

Ibogaine has killed people from cardiac failure. The EO just put it on a fast track.

The executive order skips the parts of drug approval that exist for a reason. The FDA rejected MDMA not because it doesn't work but because the evidence wasn't complete — insufficient durability data, cardiovascular risks, selection bias in trial participants. Priority vouchers compress review timelines from months to weeks. That's not "accelerating" safety review — it's abbreviating it.

Ibogaine is the most dangerous inclusion. Nora Volkow, director of the National Institute on Drug Abuse, flagged ibogaine's cardiac toxicity as a "major concern" that "might stand in the way of approval." Multiple deaths have been documented in the medical literature linked to ibogaine-related cardiac events. The EO directs FDA and DEA to open a Right to Try pathway for ibogaine, but Right to Try requires that drugs have "met basic safety requirements" — and ibogaine's status on that threshold is unclear at best.

The speed is the problem, not the science. Scientists have questioned whether the fast-track approach sacrifices reproducibility as the gold standard for drug approval. Persistent adverse events affected 16% of one cohort, rising to 31% among patients with prior personality disorders — a four-fold elevated risk. I. Glenn Cohen at Harvard Law noted the EO has "less to say about reimbursement and delivery mechanisms," which he views as necessary for real access. The order creates a pathway without building the infrastructure to use it safely.

3. This Is an Industry Play Dressed as a Health Policy (Market Analysts, Compass Pathways)

The psychedelics market is projected to hit $5 billion by 2034. Someone had to open the gate.

The executive order creates immediate value for companies already in the pipeline. Compass Pathways, whose COMP360 psilocybin treatment is on track for potential approval in late 2026 or early 2027, commended the EO the day it was signed. Priority vouchers could accelerate their timeline by 9-12 months. AbbVie has already made a $1.2 billion acquisition in the psychedelic space — the first by a traditional pharma company.

The market projections explain the political alignment. The global psychedelics market is valued at $1.82 billion in 2025 and projected to reach $5.16 billion by 2034. Psilocybin holds roughly 34% of market share, with PTSD treatments growing at 17.3% annually. This isn't a niche — it's an emerging pharmaceutical sector with the kind of growth that attracts lobbying.

The bipartisan support makes more sense as economics than ideology. RFK Jr. has personal conviction. Veterans groups have urgent need. But the EO's structure — priority vouchers, Right to Try expansion, scheduling review — reads like a regulatory framework designed to accelerate market entry. Mason Marks at Harvard noted the EO overlooks religious use of ibogaine entirely, suggesting the focus is pharmaceutical, not holistic. The question isn't whether psychedelics work. It's who profits from the speed at which they reach the market.

Where This Lands

The science on psychedelics for PTSD and depression is real, and the FDA's 2024 MDMA rejection left a gap between evidence and access that someone was going to fill. Trump filled it with an executive order flanked by Joe Rogan and RFK Jr. — which tells you something about the politics, if not the policy. Veterans who've run out of options may get treatment faster. Patients in vulnerable populations may get treatment before the safety data is complete. And the companies that have spent years in clinical trials just got a regulatory shortcut worth billions. Whether that's a breakthrough or a cautionary tale depends on what the next two years of approvals look like — and whether the infrastructure for safe delivery catches up to the speed of the pipeline.

Sources